ALDX - CIK 0001341235
The table below shows Aldeyra Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$33.35M | -$43.21M | -$30.33M | -$56.64M | -$42.56M | -$37.49M |
| Capital expenditure | - | - | $0.00 | $16.32K | $7.81K | - |
| Investing cash flow | $47.74M | -$44.92M | $30.00M | -$29.95M | -$7.81K | $29.02M |
| Dividends paid | - | - | - | - | - |
Aldeyra Therapeutics, Inc. reported operating cash flow of -$33.35M for fiscal year 2025. That is up 22.8% from -$43.21M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$19.22M (FY 2017) to -$33.35M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $1.12M | -$171.42K | -$1.27M | $1.22M | $194.50M | $41.90M |